BACKGROUND: @entity3605 ( @entity3605 ) is a rapidly progressive and fatal @entity179 for which there is no noninvasive and disease-specific test for premortem diagnosis. Previous studies have suggested that, in the proper clinical context, the 14-3-3 protein in cerebrospinal fluid is a reliable marker for @entity13895 . OBJECTIVE: To assess the sensitivity of the cerebrospinal fluid 14-3-3 protein test among @entity1 with @entity13895 . DESIGN AND SETTING: We reviewed cases of @entity13895 referred to our institution that were ultimately proved by pathological examination and on which cerebrospinal fluid 14-3-3 testing had been performed. @entity1 : @entity1 with @entity3605 referred to our institution for clinical and/or pathological evaluation (biopsy- or autopsy-confirmed diagnosis) from January 1, 1998, through July 15, 2002, and on whom 14-3-3 testing had been performed. Thirty-two such @entity1 with @entity13895 were identified. Main Outcome Measure The 14-3-3 test results, from various laboratories, in these 32 @entity1 . RESULTS: Seventeen of the 32 @entity1 had a positive result for the 14-3-3 test, yielding a sensitivity of only 53%. A positive 14-3-3 result was significantly correlated with a shorter time between disease onset and the lumbar puncture for the 14-3-3 test. CONCLUSIONS: Testing for the 14-3-3 protein is only modestly sensitive to @entity13895 , and we caution against ruling out a diagnosis of the disease on the basis of a negative 14-3-3 result.

Challenging the clinical utility of the 14-3-3 protein for the diagnosis of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS'] @entity13895 :: ('MESH:C565143', 'Disease') :: ['definite sporadic CJD', 'sporadic CJD'] @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disorder'] @entity3605 :: ('MESH:D007562', 'Disease') :: ['Creutzfeldt-Jakob disease', 'CJD']
@entity13895 :: (MESH:C565143,Disease) :: ['sporadic Creutzfeldt-Jakob disease']
